Zura BioZURA
Immunology5 cited findings · profile updated 2026-08-25
5.77 USDnot live — refreshed daily
About Zura Bio
Zura Bio (ZURA) is an immunology-focused company. Its drug tibulizumab has demonstrated high target engagement for both IL-17 and BAFF. Specifically, tibulizumab achieved a median trough target engagement for IL-17 of >98% and for BAFF of >98% in peripheral blood at a 300 mg Q4W dose. Tibulizumab also exhibits strong binding affinities, with an IL-17A/A binding affinity (KD) of ~14 pM and an IL-17A/F binding affinity (KD) of ~90 pM.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Median trough target engagement for IL-17 and BAFF (300 mg Q4W) | >98% | Zura Bio Ltd — SEC 8-K (2026-08-17), p.9 |
| Tibulizumab IL-17A/A binding affinity (KD) | ~14 pM | Zura Bio Ltd — SEC 8-K (2026-08-17), p.12 |
| Tibulizumab IL-17A/F binding affinity (KD) | ~90 pM | Zura Bio Ltd — SEC 8-K (2026-08-17), p.12 |
| Median trough target engagement for IL-17 | >98% | Zura Bio Ltd — SEC 8-K (2026-08-11), p.5 |
| Median trough target engagement for BAFF | >98% | Zura Bio Ltd — SEC 8-K (2026-08-11), p.5 |
Key projects
- tibulizumab
Median trough target engagement for IL-17 and BAFF in peripheral blood at 300 mg Q4W was >98%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →